Business Context and Reporting Period
Company: NanoViricides, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2012
Business Overview: NanoViricides is a development-stage biopharmaceutical company focused on discovering, developing, and commercializing nanomedicine-based therapeutics for viral diseases. The company utilizes proprietary "nanoviricide" technology (TheraCour®) to create drugs that target and neutralize viruses. As of the reporting date, the company has no commercial products and has not generated any revenue.
Key Financial Metrics
| Metric | Year Ended June 30, 2012 | Year Ended June 30, 2011 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(6,207,207) | $(6,477,165) |
| Research & Development Expenses | $4,234,138 | $4,155,846 |
| General & Administrative Expenses | $1,854,719 | $2,273,609 |
| Cash and Cash Equivalents (Ending) | $14,274,985 | $9,224,023 |
| Accumulated Deficit | $(29,424,116) | $(23,216,909) |
| Working Capital | $12,809,544 | $8,969,141 |
Note: The company reported no long-term debt as of June 30, 2012. Liquidity is supported by cash reserves and recent financing activities.
Material Changes vs. Prior Period
- Net Loss Reduction: The net loss decreased by approximately $270,000 compared to the prior year, primarily due to a reduction in General and Administrative expenses ($418,890 decrease) offset by a slight increase in R&D expenses ($78,292 increase).
- Cash Position: Cash and cash equivalents increased by approximately $5.05 million, driven by successful capital raises. The company raised $5 million in Series C Convertible Preferred Stock in June 2012 and had previously raised $5 million in Series B stock in late 2011/early 2012.
- Derivative Liability: A significant increase in derivative liability was recorded, rising from $17,519 in 2011 to $1,078,698 in 2012, reflecting the fair value adjustments of convertible preferred stock features.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Pipeline Progress: The company declared a clinical candidate for influenza (NV-INF-1) and held a pre-IND meeting with the FDA in March 2012. Subsequent to the fiscal year end, the company announced the development of an orally effective anti-influenza drug candidate (FluCide) effective against H1N1 and H3N2 strains.
- Manufacturing: The company is in the process of securing a facility in Shelton, CT (via Inno-Haven, LLC) to establish cGMP manufacturing capabilities, aiming to begin production within one year.
- Capital Requirements: Management estimates current cash reserves will fund operations through June 2014. However, an additional $10 million to $15 million is required over the next 24 months to complete toxicology studies, file an Investigational New Drug (IND) application, and establish cGMP facilities.
Risks and Contingencies
- Development Stage: The company has no approved products and no revenue. All drug candidates are in pre-clinical stages. There is no assurance that any candidate will receive regulatory approval or become commercially viable.
- Financing Risk: Continued operations depend on raising additional capital. Failure to secure funding could force the company to curtail R&D or cease operations.
- Internal Controls: Management and auditors identified a material weakness in internal control over financial reporting due to a lack of segregation of duties and the absence of an independent audit committee (remediated in June 2012 with the appointment of an independent director).
- Related Party Transactions: The company relies on TheraCour Pharma, Inc. (controlled by the company's President) for core technology licensing and manufacturing, creating potential conflicts of interest.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the $14.27 million cash balance and the projected burn rate to confirm the ability to operate through mid-2014.
- Financing Terms: Review the terms of the Series B and Series C Convertible Preferred Stock, specifically the conversion formulas (VWAP discounts) and dividend accruals, to assess potential dilution to common shareholders.
- Regulatory Milestones: Monitor the status of the pre-IND meeting outcomes for NV-INF-1 and the timeline for filing the full IND application.
- Related Party Costs: Scrutinize the development fees paid to TheraCour Pharma, Inc. ($2.96 million in 2012) to ensure they are consistent with market rates for similar services.
- Derivative Liability: Understand the impact of the $1.08 million derivative liability on the balance sheet and how future stock price volatility could affect this figure.